User further acknowledges and agrees that any use of information, images, logos, text, photographs, videos, copyrights, servicemarks, trademarks, or content contained in this site shall not be used, reproduced, rebroadcasted, altered, modified, or otherwise exploited in any manner, unless User obtains the express written consent of the Company
However, while clinical trial results have been promising for PD, they have been less favorable in AD
Thoughts on valuation and guru activity Valuing Eli Lilly right now is a challenge because it moves more like a growth stock than a value stock
Combined SGLT2 inhibitor and GLP-1 receptor agonist therapy could provide additional cardiovascular and renal benefits for adults with type 2 diabetes, according to data from a meta-analysis published in The Lancet Diabetes & Endocrinology